 Method of delivering powder transdermally with needless injector |
| What we claim is: 1. A method of therapeutic treatment, comprising transdermally delivering ... |
|
| Telomere repeat binding factors and diagnostic and therapeutic use thereof |
| The present invention provides vertebrate telomeric binding factors (TRFs) that bind to the TTAGGG ... |
|
| Protease-activated receptor PAR4 (ZCHEMR2) |
| What is claimed is: 1. An isolated polynucleotide molecule that encodes a polypeptide comprising ... |
|
| Systemic drug delivery compositions comprising a polycationi substance |
| I claim: 1. A method of systemically delivering a pharmaceutically effective amount of a ... |
|
| Nucleic acid-containing composition, its preparation and use |
| We claim: 1. A composition comprising a deoxyribonucleic acid and a cationic oligopeptide that ... |
|
| Peptide-enhanced cationic lipid transfections |
| OF THE INVENTION The present invention provides improved methods for transfecting eukaryotic cells ... |
|
| Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| It is therefore an object of the present invention to provide a controlled release formulation of a ... |
|
| Xylofuranosly-containing nucleoside phosphoramidites and polynucleotides |
| What is claimed is: 1. A compound having the formula I: ##STR5## wherein, R.sub.1 is OH, O--R.sub.3,... |
|
| Substituted indazole-O-glucosides |
| OF THE INVENTION All diabetics, regardless of their genetic and environmental backgrounds, have in ... |
|
| Production in Escherichia coli of extracellular Serratia spp. hydrolases |
| We claim: 1. A method of producing an extracellular hydrolytic Serratia spp. enzyme selected from ... |
|
|
Pharmaceutical composition for diabetic neuropathy
| Details |
Inventors: Endo, Kazuki; Abiru, Toichi; Kamei, Junzo;
Assignee: Yamasa Corporation (Chiba, JP)
Primary Examiner: Lewis; Patrick T.
Assistant Examiner:
Attorney, Agent or Firm: Wenderoth, Lind & Ponack, L.L.P.
The present invention relates to an agent for the prophylaxis or treatment of diabetic neuropathy, which contains cytidine 5'-diphosphocholine (CDP-choline) as an active ingredient. The agent for the prophylaxis or treatment of diabetic neuropathy of the present invention is effective for neuropathy mainly caused by metabolic disturbance of carbohydrate and is also superior in safety. Neuropathy includes peripheral neuropathy and dysautonomia. CDP-choline is effective even by oral administration. |
|
DETAILED DESCRIPTION What is claimed is: 1.
A method for the prophylaxis of diabetic peripheral neuropathy, which comprises administering an effective amount of cytidine 5'-diphosphocholine or a pharmaceutically acceptable salt thereof to a patient with diabetes.
2.
The method of claim 1, wherein the diabetic peripheral neuropathy is a neuropathy mainly caused by metabolic disturbance of carbohydrate.
3.
The method of claim 1, wherein the diabetic peripheral neuropathy is polyneuropathy.
4.
The method of claim 1, which comprises oral administration.
Description:
TECHNICAL FIELD TO WHICH THE INVENTION PERTAINS The present invention relates to an agent for the prophylaxis or treatment of diabetic neuropathy containing cytidine 5'-diphosphocholine (CDP-choline) as an active ingredient, a method for the prophylaxis or treatment of said disorder, comprising administering an effective amount of CDP-choline, use of CDP-choline for the production of a pharmaceutical agent for the prophylaxis or treatment of said disorder, and a pharmaceutical composition for the prophylaxis or treatment of said disorder comprising an effective amount of CDP-choline and a pharmaceutically acceptable carrier.
BACKGROUND ART At present, treatments of diabetes are symptomatic and rely on administration of insulin or hypoglycemic agents.
However, a long-term control of blood sugar is difficult, not to mention complete cure of diabetes, and in case of longer period of the disease, more diversified complications are induced.
Of such complications, a general disease state of diabetic peripheral neuropathy is bilaterally symmetrical and sensory nerve dominant polyneuropathy.
In acute symptoms, excitement of nerves such as sensory abnormality, allodynia (to feel pain by light touch of body surface) and the like is observed, and in chronic symptoms, diminished sensation (limb numbness, cold sense etc.
), pain and the like are observed.
In addition, diabetic dysautonomia is mainly developed in diabetic patients having polyneuropathy, thus putting every organ under control of autonomic nerve at risk for abnormality, and abnormal bowel movement such as constipation and diarrhea, impotence, orthostatic hypotension, dyshidrosis, gastric emptying delay and the like are observed
|
|
Gene Therapy 
